PYPD / PolyPid Ltd. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter o

Exhibit 99.1 PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 1, 2026 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2026 Commission File Number: 001-3842

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2026 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2026 Commission File Number: 001-38428

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2026 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) In

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results Initiated NDA Submission to the FDA for D-PLEX₁₀₀; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for

Exhibit 99.1 PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results Initiated NDA Submission to the FDA for D-PLEX₁₀₀; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharm

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track

Exhibit 99.1 PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to im

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2026 Commission File Number: 001-384

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2026 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 Nos. 333-276826, 333-280658, 333-281863,333-284376 and 333-289034) of PolyPid Ltd. (2) Registration Statements (Form S-8 Nos. 333-239517, 333-271060, 333-277703, 333-280662 and 333-289570) pertaining to th

CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.

CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)

Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Jonny Missulawin, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such sta

CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)

Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dikla Czaczkes Akselbrad, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which

PolyPid Ltd. Insider Trading Policy Effective February 9, 2026

Exhibit 11.1 PolyPid Ltd. Insider Trading Policy Effective February 9, 2026 I. Introduction This policy determines acceptable transactions in the securities of PolyPid Ltd. (the “Company”) by our employees, directors, consultants and other related persons. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publi

Description of Rights of Each Class of Securities

Exhibit 2.3 Description of Rights of Each Class of Securities The following description of Polypid Ltd. (the “Company”) share capital, provisions of our amended and restated articles of association as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our amended and res

CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2026 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2026 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offic

POLYPID LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.3 POLYPID LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Tal Vilnai, Secretary and General Counsel of PolyPid Ltd. (the “Company”), and Ms. Orna Blum, Assistant Secretary and Legal Counsel of the Company, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 3) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

polypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on FEBRUARY 4, 2026

Exhibit 99.1 polypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on FEBRUARY 4, 2026 Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of PolyPid Ltd. (“PolyPid” or the “Company”) will be held on February 4, 2026 at 2:00 p.m. Israel time at the Company’s office, located at 18 Hasivim Street, Petach Tikva 4959376, Israel, for th

POLYPID LTD. PETACH TIKVA, ISRAEL

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 4, 2026 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company” or “our,” “we” or “us”) for use at the Company’s extraordinary general meeting of shareholders (the “Meeting”) to be held on February 4, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 2) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX100 New Drug Application Submission

Exhibit 99.1 PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX100 New Drug Application Submission PETACH TIKVA, Israel – December 16, 2025 – PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outc

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission NDA to be Submitted on a Rolling Basis, Beginning Early 2026

Exhibit 99.1 PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission NDA to be Submitted on a Rolling Basis, Beginning Early 2026 PETACH TIKVA, Israel – December 3, 2025 – PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Appl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offic

Up to $15,000,000 Ordinary Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-280658 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated July 12, 2024) Up to $15,000,000 Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated July 12, 2024, filed with the Securities and Exchange Commission as a part of our registration statement on Form F-3 (File No. 333-280658), or the Reg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 (Report No. 2) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Succ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offi

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀ Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of

Exhibit 99.1 PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀ Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of D-PLEX₁₀₀ Following Successful SHIELD II Phase 3 Trial PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 (Report No. 3) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal ex

CALCULATION OF FILING FEE TABLES PolyPid Ltd. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 PolyPid Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, no par

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2025, and for the Six Months then Ended

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2025, and for the Six Months then Ended Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 (Report No. 2) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal ex

As filed with the Securities and Exchange Commission on August 13, 2025

As filed with the Securities and Exchange Commission on August 13, 2025 Registration No.

POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 U.S. DOLLARS IN THOUSANDS

Exhibit 99.1 POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condensed Consolidated Statements of Operations 4 Interim Condensed Consolidated Statements of Shareholders’ Equity 5 - 7 Interim Condensed Consolidated Statements of Cash Fl

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI; NDA submission expected in

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI; NDA submission expected in Q1 2026; Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and Diabetes Market; Successful Warrant E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline

Exhibit 99.1 PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline PETACH TIKVA, Israel, August 12, 2025 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel August 4, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PolyPid Ltd. (CIK 0001611842) Registration Statement No. 333-289034 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PolyPid Ltd. (the “Registrant”) hereby requests acceleration of the effe

LETTER

August 4, 2025 Dikla Czaczkes Akselbrad Chief Executive Officer PolyPid Ltd. 18 Hasivim Street Petach Tikva 4959376, Israel Re: PolyPid Ltd. Registration Statement on Form F-3 Filed July 29, 2025 File No. 333-289034 Dear Dikla Czaczkes Akselbrad: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for

CALCULATION OF FILING FEE TABLES PolyPid Ltd. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 PolyPid Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares (1) Othe

As filed with the Securities and Exchange Commission on July 29, 2025

As filed with the Securities and Exchange Commission on July 29, 2025 Registration No.

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market PolyPid’s proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for

Exhibit 99.1 PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market PolyPid’s proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid’s product p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 Commission File Number: 001-3842

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 3) Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal exec

Compensation Policy PolyPid Ltd. (the “Company”) Compensation Policy for Officers and Directors of the Company

Exhibit 99.1 Compensation Policy PolyPid Ltd. (the “Company”) Compensation Policy for Officers and Directors of the Company Table of Contents 1. Background 1 2. Compensation Objectives 1 3. Compensation policy 2 3.1. Officers’ Compensation Package Components 2 3.2. Parameters for reviewing compensation terms 2 3.3. Ratio between Fixed Compensation and Variable Compensation 3 3.4. Base Salary 3 3.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 2) Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal exec

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Exhibit 99.1 PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results ● The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (“FDA”) Approval of D-PLEX₁₀₀. ● The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial; D-PLE

ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel

Exhibit 10.1 PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel June 16, 2025 To the Holders of Ordinary Shares Purchase Warrants Issued on January 9, 2024 and December 26, 2024 Re: Inducement Offer to Exercise Existing Ordinary Shares Purchase Warrants Dear Holder: PolyPid Ltd. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) th

PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 Commission File Number: 001-3842

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) I

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Exhibit 99.1 PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints ● D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions. ● The trial suc

POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN

Exhibit 99.1 POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN 1. Definitions As used herein capitalized terms shall have the meanings set forth in Annex A hereto, unless the context clearly indicates to the contrary. 2. The Plan 2.1 Purpose The purpose and intent of the Plan is to advance the interests of the Company by affording to selected employees, officers, directors, consultants and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 3) Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal execu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 2) Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal execu

POLYPID LTD. PETACH TIKVA, ISRAEL

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 25, 2025 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company” or “our,” “we” or “us”) for use at the Company’s annual and extraordinary general meeting of shareholders (the “Meeting”) to be he

polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on June 25, 2025

Exhibit 99.1 polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on June 25, 2025 Notice is hereby given that an Annual and Extraordinary General Meeting of Shareholders (the “Meeting”) of PolyPid Ltd. (“PolyPid” or the “Company”) will be held on June 25, 2025 at 2:00 p.m. Israel time at the Company’s office, located at 18 Hasivim Street, Petach Tikva 4959376

POLYPID LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.3 POLYPID LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Tal Vilnai, Secretary and General Counsel of PolyPid Ltd. (the “Company”), and Ms. Orna Blum, Assistant Secretary and Legal Counsel of the Company, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and t

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Re

Exhibit 99.1 PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 Commission File Number: 001-38428

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 Commission File Number: 001-384

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment o

Exhibit 99.1 PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of a

THIRD AMENDMENT (this “Amendment”) Dated January 6, 2025

Exhibit 4.20 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, IDENTIFIED BY [***], HAS BEEN EXCLUDED FROM THIS DOCUMENT PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT POLYPID LTD. TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT (this “Amendment”) Dated January 6, 2025 to: that certain AGREEMENT FOR THE PROVISION OF A LOAN FAC

CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)

Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Jonny Missulawin, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such sta

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 Nos. 333-276826, 333-280658, 333-281863 and 333-284376) of PolyPid Ltd. (2) Registration Statements (Form S-8 Nos. 333-239517, 333-271060, 333-277703 and 333-280662) pertaining to the equity incentive plan

PolyPid Ltd. Insider Trading Policy Effective February 10, 2025

Exhibit 11.1 PolyPid Ltd. Insider Trading Policy Effective February 10, 2025 I. Introduction This policy determines acceptable transactions in the securities of PolyPid Ltd. (the “Company”) by our employees, directors, consultants and other related persons. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publ

Description of Rights of Each Class of Securities

Exhibit 2.3 Description of Rights of Each Class of Securities Type and Class of Securities PolyPid Ltd.’s (the “Company”) authorized share capital consists of 107,800,00 ordinary shares, no par value per share (“Ordinary Shares”). Registration Number and Purposes and Objects of the Company The Company’s registration number with the Israeli Registrar of Companies is 51-410592-3. The Company’s purpo

CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.

CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)

Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dikla Czaczkes Akselbrad, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 rosalindpypdexa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of POLYPID LTD. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Director

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025 Company Completed Pri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 rosalindpypdexa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of POLYPID LTD. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Director

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel January 28, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PolyPid Ltd. (CIK 0001611842) Registration Statement No. 333-284376 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PolyPid Ltd. (the “Registrant”) hereby requests acceleration of the ef

LETTER

January 24, 2025 Dikla Czaczkes Akselbrad Chief Executive Officer PolyPid Ltd. 18 Hasivim Street Petach Tikva 4959376, Israel Re: PolyPid Ltd. Registration Statement on Form F-3 Filed January 21, 2025 File No. 333-284376 Dear Dikla Czaczkes Akselbrad: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding request

Calculation of Filing Fee Table (Form Type) POLYPID LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) POLYPID LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1)(2) Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3)(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fe

As filed with the Securities and Exchange Commission on January 21, 2025

As filed with the Securities and Exchange Commission on January 21, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

REGISTRATION RIGHTS AGREEMENT

Exhibit 99.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 23, 2024, between PolyPid Ltd., an Israeli company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement,

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients with a Concurrent Private Placement of up to $41 Million

Exhibit 99.1 PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients with a Concurrent Private Placement of up to $41 Million ● 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; ● Upon Potential Positive Phase 3 Data the Company Expects to Submit a New D

PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 (Report No. 2) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 99.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

SECURITIES PURCHASE AGREEMENT

Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 23, 2024 by and among PolyPid Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set fo

PYPD / PolyPid Ltd. / Lukach Aharon - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea0224424-13ga1lukachpoly.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* PolyPid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offic

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Exhibit 99.1 PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy PETACH TIKVA, Israel, December 11, 2024 (GLOBE NEWSWIRE) – PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with I

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

Exhibit 99.1 PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance PETACH TIKVA, Israel, November 29, 2024 (GLOBE NEWSWIRE) – PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notification (the “Notification Letter”) from the Listing Q

PYPD / PolyPid Ltd. / Nir Yehuda - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea0223049-13ga1nirpolypid.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* PolyPid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 3) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 Unblinded Interim Analysis Outcome Expected Later this Qua

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 Unblinded Interim Analysis Outcome Expected Later this Quarter SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in First Quarter of 2025 Conference Call

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-38428 POLYPID LTD. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal e

Up to $8,250,000 Ordinary Shares

Filed pursuant to Rule 424(b)(5) Registration No. 333-280658 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2024) Up to $8,250,000 Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with Oppenheimer & Co. Inc., or Oppenheimer, dated November 8, 2024, relating to the sale of our ordinary shares, no par value, or the Ordinary Shares, offered by this prospectus suppl

POLYPID LTD. Ordinary Shares Sales Agreement

Exhibit 10.1 POLYPID LTD. Ordinary Shares Sales Agreement November 8, 2024 Oppenheimer & Co. Inc. 85 Broad Street New York, NY 10004 Ladies and Gentlemen: POLYPID LTD., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Ordinary Shares. The Company agrees

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-38428 POLYPID LTD. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

PYPD / PolyPid Ltd. / Centaurus Investments Ltd - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea0217289-13ga1centpolypid.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* PolyPid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of

PYPD / PolyPid Ltd. / Rosalind Advisors, Inc. Passive Investment

SC 13G/A 1 rosalindpypd13ga1sep2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 POLYPID LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M8001Q126 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 rosalindpypdexafeb202.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of POLYPID LTD. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Di

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted During

Exhibit 99.1 PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted During the Current Quarter Top-line Results Anticipated in First Quarter of 2025 PETACH TIKVA, Israel, October 1, 2024 (GLOBE NEWSWIRE) – PolyP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

LETTER

September 5, 2024 Dikla Czaczkes Akselbrad Chief Executive Officer PolyPid Ltd. 372 Franklin Ave. P.O. Box 558 Nutley, NJ 07110 Re: PolyPid Ltd. Registration Statement on Form F-3 Filed August 30, 2024 File No. 333-281863 Dear Dikla Czaczkes Akselbrad: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding reques

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel September 5, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PolyPid Ltd. (CIK 0001611842) Registration Statement No. 333-281863 |on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PolyPid Ltd. (the “Registrant”) hereby requests acceleration of the

Calculation of Filing Fee Table (Form Type) POLYPID LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) POLYPID LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1)(2) Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3)(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fe

As filed with the Securities and Exchange Commission on August 30, 2024

As filed with the Securities and Exchange Commission on August 30, 2024 Registration No.

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 rosalindpypdexafeb202.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of POLYPID LTD. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 3) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal ex

POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS

Exhibit 99.1 POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 1 - 2 Interim Condensed Consolidated Statements of Operations 3 Interim Condensed Consolidated Statements of Shareholders’ Equity (Deficit) 4 - 6 Interim Condensed Consolidated Statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 2) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal ex

PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Inte

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up, Which is Expected in Fourth Quarter of 2024

PYPD / PolyPid Ltd. / Rosalind Advisors, Inc. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 POLYPID LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M8001Q126 (CUSIP Number) August 06, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2024, and for the Six Months then Ended

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2024, and for the Six Months then Ended Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. F

ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 99.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

SECURITIES PURCHASE AGREEMENT

Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 1, 2024 by and among PolyPid Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds Funding Extends Company’s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More tha

Exhibit 99.1 PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds Funding Extends Company’s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

REGISTRATION RIGHTS AGREEMENT

Exhibit 99.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 1, 2024, between PolyPid Ltd., an Israeli company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, da

SECOND AMENDMENT (this “Amendment”) Dated August 1, 2024

Exhibit 99.6 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO POLYPID LTD., IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. SECOND AMENDMENT (this “Amendment”) Dated August 1, 2024 to: that certain AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 2) Commission file nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 2) Commission file number: 001-38428 POLYPID LTD. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal execu

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel July 10, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PolyPid Ltd. (CIK 0001611842) Registration Statement No. 333-280658 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PolyPid Ltd. (the “Registrant”) hereby requests acceleration of the effec

LETTER

July 9, 2024 Dikla Akselbrad Chief Executive Officer PolyPid Ltd. 372 Franklin Avenue Nutley, NJ 07110 Re: PolyPid Ltd. Registration Statement on Form F-3 Filed July 2, 2024 File No. 333-280658 Dear Dikla Akselbrad: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you th

As filed with the Securities and Exchange Commission on July 2, 2024

As filed with the Securities and Exchange Commission on July 2, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2024 Commission File Number: 001-3842

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) I

Calculation of Fee Filing Tables Form F-3 (Form Type) POLYPID LTD. (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Fee Filing Tables Form F-3 (Form Type) POLYPID LTD. (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For

POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN

Exhibit 99.1 POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN 1. Definitions As used herein capitalized terms shall have the meanings set forth in Annex A hereto, unless the context clearly indicates to the contrary. 2. The Plan 2.1 Purpose The purpose and intent of the Plan is to advance the interests of the Company by affording to selected employees, officers, directors, consultants and

Calculation of Filing Fee Tables Form S-8 (Form Type) PolyPid Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PolyPid Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered (1) (2) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Pa

As filed with the Securities and Exchange Commission on July 2, 2024

As filed with the Securities and Exchange Commission on July 2, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2024 Commission File Number: 001-3842

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) I

PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now In

Exhibit 99.1 PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Imp

POLYPID LTD. PETACH TIKVA, ISRAEL

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 2, 2024 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company”) for use at the Company’s annual and extraordinary general meeting of shareholders (the “Meeting”) to be held on July 2, 2024, at 2

polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on July 2, 2024

Exhibit 99.1 polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on July 2, 2024 Notice is hereby given that an Annual and Extraordinary General Meeting of Shareholders (the “Meeting”) of PolyPid Ltd. (“PolyPid” or the “Company”) will be held on July 2, 2024 at 2:00 p.m. Israel time at the Company’s office, located at 18 Hasivim Street, Petach Tikva 4959376,

POLYPID LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.3 POLYPID LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Tal Vilnai, Secretary and General Counsel of PolyPid Ltd. (the “Company”) and Ms. Orna Blum, Assistant Secretary and Legal Counsel of the Company, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 (Report No. 3) Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal execu

POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN

Exhibit 99.1 POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN 1. Definitions As used herein capitalized terms shall have the meanings set forth in Annex A hereto, unless the context clearly indicates to the contrary. 2. The Plan 2.1 Purpose The purpose and intent of the Plan is to advance the interests of the Company by affording to selected employees, officers, directors, consultants and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 (Report No. 2) Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal execu

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Ce

Exhibit 99.1 PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 Commission File Number: 001-38428

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) In

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unbl

Exhibit 99.1 PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Secon

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2024 Commission File Number: 001-384

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

PYPD / PolyPid Ltd. / Lukach Aharon - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* PolyPid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M8001Q126 (CUSIP Number) Aharon Lukach c/o Eli Cohen 9, Tel Aviv,

PYPD / PolyPid Ltd. / Nir Yehuda - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* PolyPid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M8001Q126 (CUSIP Number) Yehuda Nir 14 Moshe Lerer St., Ness Zion

CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)

Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dikla Czaczkes Akselbrad, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which

As filed with the Securities and Exchange Commission on March 6, 2024

As filed with the Securities and Exchange Commission on March 6, 2024 Registration No.

Description of Rights of Each Class of Securities

Exhibit 2.4 Description of Rights of Each Class of Securities Type and Class of Securities PolyPid Ltd.’s (the “Company”) authorized share capital consists of 107,800,00 ordinary shares, no par value per share (“Ordinary Shares”). Registration Number and Purposes and Objects of the Company The Company’s registration number with the Israeli Registrar of Companies is 51-410592-3. The Company’s purpo

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 Nos. 333-257651 and 333-276826) of PolyPid Ltd., (2) Registration Statements (Form S-8 Nos. 333-239517 and 333-271060) pertaining to the equity incentive plan of PolyPid Ltd.; of our report dated March 6, 2

Calculation of Filing Fee Tables Form S-8 (Form Type) PolyPid Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PolyPid Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be P

POLYPID LTD. (the “Company”) CLAWBACK POLICY Effective as of November 6, 2023

Exhibit 97.1 POLYPID LTD. (the “Company”) CLAWBACK POLICY Effective as of November 6, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interest of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Compensa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.

CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a)

Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Jonny Missulawin, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such sta

CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

Addendum to Lease dated March 27, 2014 Made and signed in Tel Aviv on January 14, 2024

Exhibit 4.15 Addendum to Lease dated March 27, 2014 Made and signed in Tel Aviv on January 14, 2024 Between: Isras Investment Company Ltd., Company No. 520017807 Of 3 Har Sinai Street, Tel Aviv (hereinafter: the “Lessor”) Of the first part; And: PolyPid Ltd., Company No. 514105923 By its authorized signatories Of 18 HaSivim Street, Petah Tikva (hereinafter: the “Lessee”) Of the second part; Wherea

PYPD / PolyPid Ltd. / Rosalind Advisors, Inc. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 POLYPID LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M8001Q118 (CUSIP Number) February 13, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil

Joint Filing Agreement

Schedule 13G Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of POLYPID LTD.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2024 (Report No. 2) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2024 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Resu

Exhibit 99.1 PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 Million Financing Extends Company’s Cash Runway Through Late Q3 2024 and Beyond

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unbl

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Seco

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel

PolyPid Ltd. 18 Hasivim Street Petach Tikva 495376, Israel February 12, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PolyPid Ltd. (CIK 0001611842) Registration Statement No. 333-276826 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PolyPid Ltd. (the “Registrant”) hereby requests acceleration of the e

LETTER

United States securities and exchange commission logo February 9, 2024 Dikla Czaczkes Akselbrad Chief Executive Officer PolyPid Ltd.

As filed with the Securities and Exchange Commission on February 1, 2024

As filed with the Securities and Exchange Commission on February 1, 2024 Registration No.

Calculation of Filing Fee Table (Form Type) POLYPID LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) POLYPID LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1)(2) Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3)(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2024 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 99.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

REGISTRATION RIGHTS AGREEMENT

Exhibit 99.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 4, 2024, between PolyPid Ltd., an Israeli company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, d

PolyPid Announces Private Placement for $16 Million in Gross Proceeds Financing Led by Leading U.S. Life Sciences-focused Investors

Exhibit 99.1 PolyPid Announces Private Placement for $16 Million in Gross Proceeds Financing Led by Leading U.S. Life Sciences-focused Investors PETACH TIKVA, Israel, January 4, 2024 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private pl

SECURITIES PURCHASE AGREEMENT

Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 4, 2024 by and among PolyPid Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set fort

PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT POLYPID LTD.

Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2023 (Report No. 2) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colore

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal

Exhibit 99.1 PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal PETACH TIKVA, Israel, November 7, 2023 (GLOBE NEWSWIRE) – PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical ou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission file number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission file number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Exhibit 99.1 PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule PETACH TIKVA, Israel, October 11, 2023 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2023 (Report No. 3) Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2023 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal e

POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN

Exhibit 99.1 POLYPID LTD. AMENDED AND RESTATED 2012 SHARE OPTION PLAN 1. Definitions As used herein capitalized terms shall have the meanings set forth in Annex A hereto, unless the context clearly indicates to the contrary. 2. The Plan 2.1 Purpose The purpose and intent of the Plan is to advance the interests of the Company by affording to selected employees, officers, directors, consultants and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2023 (Report No. 2) Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal e

JOINT FILING AGREEMENT

EX-99.1 2 ea185222ex99-1polypid.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of ordinary shares of PolyPid Ltd. Each of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 (Report No. 4) Commission F

6-K 1 ea185477-6kpolypidltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 (Report No. 4) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18

PolyPid Announces Reverse Share Split

Exhibit 99.1 PolyPid Announces Reverse Share Split PETACH TIKVA, Israel, September 20, 2023 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, suc

PYPD / Polypid Ltd / Centaurus Investments Ltd - SCHEDULE 13G Passive Investment

SC 13G 1 ea185222-13gcentpolypid.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* PolyPid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M8001Q118 (CUSI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 (Report No. 3) Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

polypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on September 18, 2023

Exhibit 99.1 polypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on September 18, 2023 Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of PolyPid Ltd. (“PolyPid” or the “Company”) will be held on September 18, 2023 at 2:00 p.m. Israel time at the Company’s office, located at 18 Hasivim Street, Petach Tikva 495376, Israel, for

POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 9, 2023

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 9, 2023 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company”) for use at the Company’s extraordinary general meeting of shareholders (the “Meeting”) to be held on October 9, 2023, at 2:00 p.m. Israel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offi

POLYPID LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.3 POLYPID LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Tal Vilnai, Secretary and General Counsel of PolyPid Ltd. (the “Company”) and Ms. Orna Blum, Assistant Secretary and Legal Counsel of the Company, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 (Report No. 2) Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

polypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on october 9, 2023

Exhibit 99.1 polypid Ltd. Notice of EXTRAORDINARY General Meeting of shareholders to be held on october 9, 2023 Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of PolyPid Ltd. (“PolyPid” or the “Company”) will be held on October 9, 2023 at 2:00 p.m. Israel time at the Company’s office, located at 18 Hasivim Street, Petach Tikva 495376, Israel, for the f

POLYPID LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.3 POLYPID LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Tal Vilnai, Secretary and General Counsel of PolyPid Ltd. (the “Company”) and Ms. Orna Blum, Assistant Secretary and Legal Counsel of the Company, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to

POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 18, 2023

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 18, 2023 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company”) for use at the Company’s extraordinary general meeting of shareholders (the “Meeting”) to be held on September 18, 2023, at 2:00 p.m. I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2023 (Report No. 2) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed

Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of

POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS

Exhibit 99.1 POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condensed Consolidated Statements of Operations 4 Interim Condensed Consolidated Statements of Shareholders’ Equity 5 - 6 Interim Condensed Consolidated Statements of Cash Fl

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2023, and for the Six Months then Ended

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2023, and for the Six Months then Ended Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2023 (Report No. 2) Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal exec

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Exp

Exhibit 99.1 PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2023 Commission File Number: 001-3842

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) I

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

EX-99.1 2 ea179783ex99-1polypid.htm PRESS RELEASE ISSUED BY POLYPID LTD. ON JUNE 5, 2023, TITLED "POLYPID ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID REQUIREMENT AND TRANSFER OF ITS LISTING TO THE NASDAQ CAPITAL MARKET." Exhibit 99.1 PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Ca

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections Recruitment to Resume Imminently Top-line Results Expected in Mid-2024

Exhibit 99.1 PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections Recruitment to Resume Imminently Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, May 22, 2023 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2023 (Report No. 3) Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2023 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal execu

Up to $8,706,775 Ordinary Shares

424B5 1 ea178838-424b3polypid.htm FORM 424B3 Filed Pursuant to Rule 424(b)(5) Registration No. 333-257651 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) Up to $8,706,775 Ordinary Shares This prospectus supplement updates and amends certain information contained on the cover page of the prospectus, dated July 9, 2021, or the 2021 prospectus, relating to the offer and sale of our ordinary

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Amendment No.

PYPD / Polypid Ltd / Aurum Ventures M.k.i. Ltd. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Polypid Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M8001Q118 (CUSIP Number) Ilan Lior General Counsel Aurum Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2023 (Report No. 2) Commission File Nu

6-K 1 ea178278-6kpolypidltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasiv

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expect

Exhibit 99.1 PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently Received Advice from the Swedish Medical Products Agency Consistent with Feedback Received from the FDA Completed

ARTICLES OF ASSOCIATION OF polypid Ltd. (as amended and restated on May 35, 20222023) THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY

Exhibit 99.2 ARTICLES OF ASSOCIATION OF polypid Ltd. (as amended and restated on May 35, 20222023) THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY PRELIMINARY 1. DEFINITIONS; INTERPRETATION. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite to them respectively, unless inconsistent with the subject or context. “Articles” shall me

ARTICLES OF ASSOCIATION OF polypid Ltd. (as amended and restated on May 5, 2023) THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY

Exhibit 99.1 ARTICLES OF ASSOCIATION OF polypid Ltd. (as amended and restated on May 5, 2023) THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY PRELIMINARY 1. DEFINITIONS; INTERPRETATION. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite to them respectively, unless inconsistent with the subject or context. “Articles” shall mean th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2023 Commission File Number: 001-38428

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office) In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2023 Commission File Number: 001-384

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

Exhibit 99.1 PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance PETACH TIKVA, Israel, April 14, 2023 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying

Form of Securities Purchase Agreement, dated March 29, 2023, by and between the Company and the purchasers named therein.

EX-10.1 5 ea176210ex10-1polypidltd.htm FORM OF SECURITIES PURCHASE AGREEMENT, DATED MARCH 29, 2023, BY AND BETWEEN THE COMPANY AND THE PURCHASERS NAMED THEREIN Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 29, 2023, by and among PolyPid Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pa

Ordinary Shares

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257651 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) Ordinary Shares This is a public offering of 14,660,000 ordinary shares, no par value or the Ordinary Shares, of PolyPid Ltd., an Israeli corporation, at a public offering price of $0.42 per Ordinary Share. We are offering all of the Ordinary Shares offered by this prospectus on a

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

EX-99.1 7 ea176210ex99-1polypidltd.htm PRESS RELEASE ISSUED BY THE COMPANY ON MARCH 28, 2023, TITLED "POLYPID ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK" Exhibit 99.1 PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares PETACH TIKVA, Israel, March 28, 2023 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma

Certification of the Principal Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.

Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Jonny Missulawin, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such sta

Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith.

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2022 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

Description of Securities (filed herewith).

Exhibit 2.2 Description of Rights of Each Class of Securities Type and Class of Securities PolyPid Ltd.’s (the “Company”) authorized share capital consists of 47,800,000 ordinary shares, no par value per share (“Ordinary Shares”). The Company will ask its shareholders to approve the increase of the authorized share capital to 107,800,000 Ordinary Shares at its upcoming annual shareholders meeting

POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 5, 2023

Exhibit 99.2 POLYPID LTD. PETACH TIKVA, ISRAEL PROXY STATEMENT ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 5, 2023 The enclosed proxy is being solicited by the board of directors (the “Board of Directors”) of PolyPid Ltd. (the “Company”) for use at the Company’s annual and extraordinary general meeting of shareholders (the “Meeting”) to be held on May 5, 2023, at 2:0

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

Exhibit 99.3 PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds ● Company Also Restructures Existing Kreos Loan, Deferring Over $3 Million of Repayment PETACH TIKVA, Israel, March 31, 2023 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”

POLYPID LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

Exhibit 99.3 POLYPID LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Tal Vilnai, Secretary and General Counsel of PolyPid Ltd. (the “Company”) and Ms. Orna Blum, Assistant Secretary and Legal Counsel of the Company, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

Exhibit 99.2 PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the pricing of an underwritten

polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on May 5, 2023

Exhibit 99.1 polypid Ltd. Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on May 5, 2023 Notice is hereby given that an Annual and Extraordinary General Meeting of Shareholders (the “Meeting”) of PolyPid Ltd. (“PolyPid” or the “Company”) will be held on May 5, 2023 at 2:00 p.m. Israel time at the Company’s office, located at 18 Hasivim Street, Petach Tikva 495376, Isr

Form of Pre-Funded Warrant.

Exhibit 4.1 Form of Pre-Funded Warrant [attached hereto] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2023 (Report No. 2) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal exe

Consent of Kost, Forer, Gabbay & Kasierer, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of Ernst & Young Global.

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-257651) of PolyPid Ltd., and (2) Registration Statement (Form S-8 No. 333-239517) pertaining to the equity incentive plan of PolyPid Ltd.; of our report dated March 31, 2023, with respect to the con

Amendment, dated March 29, 2023, by and between the Company and Kreos.

Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, IDENTIFIED BY [***], HAS BEEN EXCLUDED FROM THIS DOCUMENT PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT POLYPID LTD.TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT (this “Amendment”) Dated March 29, 2023 to: that certain AGREEMENT FOR THE PROVISION OF A LOAN FACIL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2023 (Report No. 3) Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2023 (Report No. 3) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal exe

Underwriting Agreement, date March 29, 2023, by and between the Company and the Underwriter.

Exhibit 1.1 POLYPID LTD. UNDERWRITING AGREEMENT March 29, 2023 Newbridge Securities Corporation 1200 N Federal Hwy, Suite 400 Boca Raton, Florida 33432 Ladies and Gentlemen: The undersigned, PolyPid Ltd., a company incorporated under the laws of Israel (collectively with its Subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statemen

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PolyPid Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.

Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith.

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2022 (the “Report”) by PolyPid Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the requirem

Form S-8

As filed with the Securities and Exchange Commission on March 31, 2023 Registration No.

Certification of the Principal Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.

Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dikla Czaczkes Akselbrad, certify that: 1. I have reviewed this annual report on Form 20–F of PolyPid Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which

SUBJECT TO COMPLETION, DATED MARCH 28, 2023

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257651 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2023 Commission File Number: 001-384

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office)

Repricing Notice to U.S. employee, consultant and directors.

Exhibit 99.2 February 8, 2023 Dear , Re: Repricing of Options We are happy to inform you, that on December 15, 2022, the Board of Directors of PolyPid Ltd. (“Company”) resolved to reduce the exercise price of the outstanding options previously issued to you, bearing an exercise price higher than $4.50 (the “Options”) to $0.769 (the “Resolution”), subject to your approval, as detailed in the table

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB (Amendment No.__) TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB (Amendment No.) TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☐ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☒ Excha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): POLYPID LTD. B. (1) This is an (check one): ☒ original filing for the Filer. ☐ amended filing for the Filer. C. Identify the filing in conjunction with which this Form is being filed: Name of registrant: POLYPID L

Repricing Notice to Israeli employees and directors.

Exhibit 99.1 February 8, 2023 Dear , Re: Repricing of Options We are happy to inform you, that on December 15, 2022 the Board of Directors of PolyPid Ltd. (“Company”) resolved to reduce the exercise price of the outstanding options previously issued to you under the capital gains tax route, bearing an exercise price higher than $4.50 (the “Options”) to $0.769 (the “Resolution”), subject to your ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2023 (Report No. 2) Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal

PYPD / Polypid Ltd / Gabriel Capital Management Ltd. Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* POLYPID ltd. (Name of Issuer) ordinary shares, NO PAR VALUE (Title of Class of Securities) M8001Q118 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infection

EX-99.1 2 ea172967ex99-1polypidltd.htm PRESS RELEASE ISSUED BY POLYPID LTD. ON FEBRUARY 8, 2023, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS." Exhibit 99.1 PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2023 (Report No. 2) Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2023 (Report No. 2) Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant’s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal e

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery ● Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA ● FDA Ac

Exhibit 99.1 PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery ● Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA ● FDA Acknowledged that SHIELD I Pre-specified Subgroup Results May Provide Supportive Evidence and Proposed that Current SHIELD II Trial Could P

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in

Exhibit 99.1 PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX??? in the Prevention of Surgical Site Infections in Abdominal Surgery D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care Results Consistent with SHIELD I Phase 3 Post-hoc Analy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2023 Commission File Number: 001-38428 PolyPid Ltd. (Translation of registrant?s name into English) 18 Hasivim Street Petach Tikva 495376, Israel (Address of principal executive office